These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

756 related items for PubMed ID: 14872476

  • 21. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.
    Mease PJ, Woolley JM, Singh A, Tsuji W, Dunn M, Chiou CF.
    J Rheumatol; 2010 Jun; 37(6):1221-7. PubMed ID: 20395648
    [Abstract] [Full Text] [Related]

  • 22. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study.
    Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J, METGO Study Group.
    Arthritis Rheum; 2005 May; 52(5):1360-70. PubMed ID: 15880810
    [Abstract] [Full Text] [Related]

  • 23. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis.
    Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, White B.
    J Rheumatol; 2006 Feb; 33(2):234-43. PubMed ID: 16465653
    [Abstract] [Full Text] [Related]

  • 24. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
    Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, Emery P.
    Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
    [Abstract] [Full Text] [Related]

  • 25. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
    Elewski B, Leonardi C, Gottlieb AB, Strober BE, Simiens MA, Dunn M, Jahreis A.
    Br J Dermatol; 2007 Jan; 156(1):138-42. PubMed ID: 17199580
    [Abstract] [Full Text] [Related]

  • 26. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L, Etanercept Psoriasis Study Group.
    Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
    [Abstract] [Full Text] [Related]

  • 27. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
    Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, Inman RD, Kivitz A, Zhou L, Solinger A, Tsuji W.
    Ann Rheum Dis; 2005 Nov; 64(11):1557-62. PubMed ID: 15843448
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
    Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T, Rutstein J, Baldassare A, Kaine J, Calabrese L, Dietz F, Sack M, Senter RG, Wiesenhutter C, Schiff M, Stein CM, Satoi Y, Matsumoto A, Caldwell J, Harris RE, Moreland LW, Hurd E, Yocum D, Stamler DA.
    Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
    [Abstract] [Full Text] [Related]

  • 29. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J.
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [Abstract] [Full Text] [Related]

  • 30. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.
    van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C, Pedersen R, Freundlich B, Fatenejad S.
    Ann Rheum Dis; 2006 Mar; 65(3):328-34. PubMed ID: 16079172
    [Abstract] [Full Text] [Related]

  • 31. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.
    Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, Robinson M, Kim J, Barron KS.
    Arthritis Rheum; 2005 Feb 15; 53(1):18-23. PubMed ID: 15696578
    [Abstract] [Full Text] [Related]

  • 32. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
    Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T.
    J Am Acad Dermatol; 2006 Mar 15; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
    [Abstract] [Full Text] [Related]

  • 33. Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.
    Lü LJ, Teng JL, Bao CD, Han XH, Sun LY, Xu JH, Li XF, Wu HX.
    Chin Med J (Engl); 2008 Apr 05; 121(7):615-9. PubMed ID: 18466681
    [Abstract] [Full Text] [Related]

  • 34. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis.
    Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, Lee H.
    J Clin Pharmacol; 2005 Mar 05; 45(3):246-56. PubMed ID: 15703360
    [Abstract] [Full Text] [Related]

  • 35. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.
    Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, Zimany K, Travers H, Caulfield JP.
    Arthritis Rheum; 2009 Feb 05; 60(2):335-44. PubMed ID: 19180516
    [Abstract] [Full Text] [Related]

  • 36. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis.
    Bliddal H, Terslev L, Qvistgaard E, Konig M, Holm CC, Rogind H, Boesen M, Danneskiold-Samsøe B, Torp-Pedersen S.
    Scand J Rheumatol; 2006 Feb 05; 35(5):341-5. PubMed ID: 17062431
    [Abstract] [Full Text] [Related]

  • 37. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.
    Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, Chen D, Becker JC.
    Ann Rheum Dis; 2007 Feb 05; 66(2):228-34. PubMed ID: 16935912
    [Abstract] [Full Text] [Related]

  • 38. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V.
    Arthritis Rheum; 2004 Feb 05; 50(2):364-71. PubMed ID: 14872477
    [Abstract] [Full Text] [Related]

  • 39. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
    Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmartí R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S.
    Ann Rheum Dis; 2004 Dec 05; 63(12):1594-600. PubMed ID: 15345498
    [Abstract] [Full Text] [Related]

  • 40. Etanercept in adult patients with early onset ankylosing spondylitis.
    Inman RD, Clegg DO, Davis JC, Whitmore JB, Solinger A.
    J Rheumatol; 2006 Aug 05; 33(8):1634-6. PubMed ID: 16881118
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.